What is Cycle Pharma?
Cycle Pharmaceuticals operates at the forefront of rare disease treatment, focusing on enhancing existing therapies, repurposing drugs, and innovating new formulations. With a dual presence in the UK and the United States, the company extends its support beyond medication, offering patient assistance programs and nutritional guidance. This comprehensive approach aims to address critical unmet medical needs and improve the quality of life for individuals and families affected by rare and genetic disorders.
How much funding has Cycle Pharma raised?
Cycle Pharma has raised a total of $25M across 1 funding round:
Debt
$25M
Debt (2020): $25M with participation from Deutsche Bank AG
Key Investors in Cycle Pharma
Deutsche Bank AG
Deutsche Bank AG is a global financial institution providing corporate and investment banking, private banking, and asset management services. Its involvement suggests a significant debt financing component, supporting Cycle Pharma's operational expansion and strategic initiatives.
What's next for Cycle Pharma?
The recent major strategic investment signals Cycle Pharma's transition into a scaling phase, likely enabling the expansion of its clinical trial pipeline and the acceleration of its commercialization efforts for its rare disease treatments. This capital infusion is expected to bolster its research and development capabilities, potentially leading to new therapeutic breakthroughs and a broader market reach for its specialized pharmaceutical solutions.
See full Cycle Pharma company page
